Cheng-Tao Lin

734 total citations
21 papers, 462 citations indexed

About

Cheng-Tao Lin is a scholar working on Oncology, Reproductive Medicine and Immunology. According to data from OpenAlex, Cheng-Tao Lin has authored 21 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 7 papers in Reproductive Medicine and 6 papers in Immunology. Recurrent topics in Cheng-Tao Lin's work include Ovarian cancer diagnosis and treatment (7 papers), Immune Cell Function and Interaction (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Cheng-Tao Lin is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Immune Cell Function and Interaction (5 papers) and Endometrial and Cervical Cancer Treatments (4 papers). Cheng-Tao Lin collaborates with scholars based in Taiwan, United States and Singapore. Cheng-Tao Lin's co-authors include Chyong‐Huey Lai, Angel Chao, Alex C. Wang, Ya-Chea Tsai, Liangmei He, T.‐C. Wu, Chi‐Mu Chuang, Ronald D. Alvarez, Chih-Wen Tseng and Archana Monie and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and American Journal of Obstetrics and Gynecology.

In The Last Decade

Cheng-Tao Lin

19 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheng-Tao Lin Taiwan 12 168 161 102 92 86 21 462
Abigail L. Sedlacek United States 11 191 1.1× 268 1.7× 58 0.6× 111 1.2× 59 0.7× 18 477
Garron J. Solomon United States 9 101 0.6× 31 0.2× 55 0.5× 124 1.3× 78 0.9× 15 367
J.A. Vidart Spain 9 110 0.7× 51 0.3× 90 0.9× 62 0.7× 67 0.8× 25 347
George Vlahos Greece 12 274 1.6× 202 1.3× 241 2.4× 182 2.0× 124 1.4× 22 663
Gaiko Ueda Japan 16 122 0.7× 77 0.5× 192 1.9× 145 1.6× 162 1.9× 53 607
Mario L. Marques‐Piubelli United States 14 269 1.6× 90 0.6× 27 0.3× 85 0.9× 98 1.1× 47 480
Amnon Amit Israel 10 408 2.4× 55 0.3× 328 3.2× 237 2.6× 104 1.2× 31 739
Suzette M. Svoboda-Newman United States 10 119 0.7× 40 0.2× 153 1.5× 164 1.8× 44 0.5× 10 541
Ciaran O’Neill United Kingdom 9 153 0.9× 32 0.2× 226 2.2× 91 1.0× 141 1.6× 13 598
May M.Y. Yu Hong Kong 10 61 0.4× 76 0.5× 27 0.3× 135 1.5× 82 1.0× 12 391

Countries citing papers authored by Cheng-Tao Lin

Since Specialization
Citations

This map shows the geographic impact of Cheng-Tao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheng-Tao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheng-Tao Lin more than expected).

Fields of papers citing papers by Cheng-Tao Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheng-Tao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheng-Tao Lin. The network helps show where Cheng-Tao Lin may publish in the future.

Co-authorship network of co-authors of Cheng-Tao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Cheng-Tao Lin. A scholar is included among the top collaborators of Cheng-Tao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheng-Tao Lin. Cheng-Tao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chao, Angel, Chen‐Yang Huang, Willie Yu, et al.. (2024). Molecular profiling reveals novel therapeutic targets and clonal evolution in ovarian clear cell carcinoma. BMC Cancer. 24(1). 1403–1403. 4 indexed citations
2.
Chen, Wei‐Chun, Huei‐Jean Huang, Lan‐Yan Yang, et al.. (2021). Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. Biomedical Journal. 45(5). 821–827. 10 indexed citations
3.
Wu, Chiao‐En, Meng‐Ting Peng, Pei‐Wei Huang, et al.. (2020). The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies. BMC Cancer. 20(1). 1018–1018. 30 indexed citations
4.
5.
Huang, Huei-Jean, Lan‐Yan Yang, Ren‐Chin Wu, et al.. (2019). Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma. Journal of the Formosan Medical Association. 119(4). 793–804. 10 indexed citations
6.
Peng, Hsiu‐Huei, et al.. (2018). Combined Immunotherapy (OK-432, IL-2) With Chemotherapy Decrease the Recurrence Rate in Advanced Ovarian Cancer. Reproductive Sciences. 26(2). 244–249. 15 indexed citations
7.
Wu, Ren‐Chin, Lan‐Yan Yang, Yun‐Hsin Tang, et al.. (2017). Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study. Journal of the Formosan Medical Association. 117(2). 117–125. 37 indexed citations
8.
Chao, Angel, Ting‐Chang Chang, Shih‐Ming Jung, et al.. (2016). Prevalence and clinical significance ofBRCA1/2germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 7(51). 85529–85541. 37 indexed citations
9.
Chen, Chao‐Yu, Chyong‐Huey Lai, Lan‐Yan Yang, et al.. (2015). Immunomodulatory therapy in refractory/recurrent ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology. 54(2). 143–149. 3 indexed citations
10.
Lee, Yi‐Chan, Tuan‐Jen Fang, & Cheng-Tao Lin. (2014). Metastatic Endometrial Adenocarcinoma to the Larynx: A Case Report and Discussion of Upper Airway Management. Journal of Palliative Medicine. 17(7). 867–869. 1 indexed citations
11.
Lin, Cheng-Tao, Chao‐Nin Wang, & Chyong‐Huey Lai. (2013). Immunotherapy for advanced or relapsed cervical cancer. Gynecology and Minimally Invasive Therapy. 2(1). 3–7. 11 indexed citations
12.
Tang, Yun‐Hsin, et al.. (2013). Treatment failure in endometrial cancer.. Journal of Clinical Oncology. 31(15_suppl). e16537–e16537.
13.
Chao, Angel, Chiao‐Yun Lin, Chia-Lung Tsai, et al.. (2012). Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23). Journal of Molecular Medicine. 91(2). 249–259. 20 indexed citations
14.
Chen, I-Ju, Chih‐Feng Yen, Kun‐Ju Lin, et al.. (2011). Vaccination With OK-432 Followed by TC-1 Tumor Lysate Leads to Significant Antitumor Effects. Reproductive Sciences. 18(7). 687–694. 13 indexed citations
15.
Wang, Alex C., Ren‐Chin Wu, Cheng-Tao Lin, & Min‐Chi Chen. (2008). A microbiological and immunohistochemical analysis of periurethral and vaginal tissue in women with de novo urge symptoms after mid-urethral sling procedures—a prospective case-controlled study. International Urogynecology Journal. 19(8). 1145–1150. 6 indexed citations
16.
Tseng, Chih-Wen, Chien‐Fu Hung, Ronald D. Alvarez, et al.. (2008). Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination. Clinical Cancer Research. 14(10). 3185–3192. 124 indexed citations
17.
Shaw, Sheng‐Wen, Chih‐Ping Chen, Tzu‐Hao Wang, et al.. (2007). Gene dosage change of TPTE and BAGE2 and breakpoint analysis in Robertsonian Down syndrome. Journal of Human Genetics. 53(2). 136–143. 11 indexed citations
18.
Lin, Cheng-Tao, Ting‐Chang Chang, Sheng‐Wen Shaw, et al.. (2006). Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. Vaccine. 24(37-39). 6199–6207. 19 indexed citations
19.
20.
Wang, Alex C., et al.. (2004). A histologic and immunohistochemical analysis of defective vaginal healing after continence taping procedures: A prospective case-controlled pilot study. American Journal of Obstetrics and Gynecology. 191(6). 1868–1874. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abigail L. Sedlacek Breakdown of academic impact, for papers by Garron J. Solomon Breakdown of academic impact, for papers by J.A. Vidart Breakdown of academic impact, for papers by George Vlahos Breakdown of academic impact, for papers by Gaiko Ueda Breakdown of academic impact, for papers by Mario L. Marques‐Piubelli Breakdown of academic impact, for papers by Amnon Amit Breakdown of academic impact, for papers by Suzette M. Svoboda-Newman Breakdown of academic impact, for papers by Ciaran O’Neill Breakdown of academic impact, for papers by May M.Y. Yu
Rankless by CCL
2026